Testing the McSad depression specific classification system in patients with somatic conditions: validity and...

Area of Science:

• Psychiatry and Psychology
• Medical Informatics
• Health Services Research

Background:

• Depression valuation is crucial for assessing interventions in chronic somatic conditions.
• The McSad is a depression classification system designed for valuation but lacks use in somatic patients.
• The EuroQol - 5 Dimensions (EQ-5DTM) is a commonly used classification system.

Purpose of the Study:

• To test the construct validity of the McSad in diabetes and cancer patients.
• To compare the McSad's performance against the EQ-5DTM in reflecting depression states.
• To evaluate the suitability of McSad for depression valuation in somatic conditions.

Main Methods:

• Cross-sectional data collected online and on paper from 114 diabetes and 436 cancer patients.
• Correlational analyses assessed McSad domains against depression (CES-D, PHQ-9), self-esteem (RSE), and extraversion (EPQ-e).
• Multiple linear regression compared variance in depression scores explained by McSad versus EQ-5DTM.

Main Results:

• McSad domains showed moderate to high correlations with depression measures (CES-D: .41–.70; PHQ-9: .52–.76).
• McSad exhibited low to moderate correlations with RSE (-.21–.-.48) and EPQ-e (.18–.31).
• McSad explained a significantly greater proportion of variance in depression scores (Diabetes: 73–82%; Cancer: 72%) compared to EQ-5DTM (Diabetes: 47–59%; Cancer: 47–51%).

Conclusions:

• The study supports the construct validity of the McSad in patients with somatic conditions.
• McSad demonstrates superior performance over EQ-5DTM in capturing the spectrum of depression in somatic patients.
• McSad is recommended for future depression valuation in individuals with chronic medical conditions.